Rheumatoid Arthritis Treatment MarketSize and Trends

Key statistics pertaining to the global rheumatoid arthritis treatment market:

Over time, there is damage to cartilage and mobility function of the affected joint in rheumatoid arthritis patient.

Affects nearly 1.3 million U.S. population (RheumatoidArthritis.org)
Most common in the age group of 30-60 years
Global prevalence varies in the range of 0.3% to 1% (World Health Organization)
Average annual cost of treatment may go up to US $20,000 (RheumatoidArthritis.org)
According to the Arthritis Foundation, people with RA loose more workdays compared to those affected by any other medical condition
According to a Harvard University study published in the Journal of Global Health (2017), prevalence of rheumatoid arthritis in Southeast Asian countries was 0.4%, 0.42 in western Pacific region, and 0.37% in eastern Mediterranean countries

Plethora of research work to introduce effective treatment therapies in the global rheumatoid arthritis treatment market

Introduction of newer therapies are expected to fuel growth of rheumatoid arthritis treatment market in developed nations. Emerging economies are late adapters to new technologies and therapies, thus are potential markets for brands not yet marketed in these countries. The Chinese FDA recently approved Xeljanz for RZ treatment (2017). The product is awaiting approval from the EU. Among the Asian countries, India, China, Pakistan, and Bangladesh had major prevailing rheumatoid arthritis patients as per WHO–ILAR COPCORD (International League of Associations for Rheumatology) (Community Oriented Program for Control of Rheumatic Diseases) studies (2015). Some of the products in pipeline include:

Antibodies that target collagen II, an important protein in joint cartilage (Researchers at the Department of Immunology, Genetics and Pathology, Uppsala University, Sweden)
Stem cell I.V. therapy developed by Mesoblast Ltd. to treat RA patients unresponsive to TNF drugs (phase 2 trials)